Risperidone versus haloperidol in the treatment of schizophrenia: A meta-analysis comparing their efficacy and safety

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 5, 1996, Pages 349-358

  De Oliveira, I R ^a,b   Miranda Scippa, A M A ^b   De Sena, E P ^a,b   Pereira, E L A ^b   Ribeiro, M G ^c   De Castro e Silva, E ^a   Bacaltchuk, J ^d  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Hlth Sec of the State of Bahia   (Brazil)

^c Rheumatology Division Centro Médico Do Hospital Aliança   (Brazil)

^d Janssen Cilag Farmacêutica Ltda   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030459670     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00030.x     Document Type: Article

References (35)

1. Seeman P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1, 133-152.
2. Bleich A, Brown SL, Kahn R, van Praag HM. (1988) The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14, 297-315.
3. Ceulemans DLS, Gelders YG, Hoppenbrouwers ML, Reyntjens AJM, Janssen PAJ. (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology, 85, 329-332.
4. 2 receptor blocker. Drug Development Research, 8, 205-211.
5. MacEwan GW. (1993) New antipsychotic medications: do research results relate to clinical practice? Canadian Journal of Psychiatry, 38 (Suppl. 3), 75-79.
6. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ. (1988) The biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics, 247, 661-670.
7. 2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics, 244, 685-693.
8. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica, 88, 395-402.
9. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. (1987) Meta-analysis of randomized controlled trials. New England Journal of Medicine, 316, 450-455.
10. Laupacis A, Sackett DL, Roberts RS. (1988) An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine, 318, 1728-1733.
11. Heylen SLE, Gelders YG. (1988) Risperidone versus haloperidol in psychotic patients: a multicentre double-blind comparative study. Part I: clinical report. Clinical Research Report RIS-BEL-7. Janssen Research Foundation, Belgium.
12. Chalmers TC, Smith Jr. H, Blackburn B. (1981) A method for assessing the quality of a randomized control trial. Controlled Clinical Trials, 2, 31-49.
13. Poynard T, Pignon JP. (1989) Duodenal ulcer: analyses of 293 randomized clinical trials, p. 149. John Libbey & Company, Paris.
14. Cook RJ, Sackett DL. (1995) The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal, 310, 452-454.
15. Kay SR. (1991) Positive and Negative Symptoms in Schizophrenia. Bruner/Mazel, New York.
16. Andreasen NC. (1983) The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City, U.S.A.
17. Jaeschke R, Oxman AD, Guyatt GH. (1990) To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. American Journal of Medicine, 88, 279-286.
18. Ceskova E, Svestka J. (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry, 26, 121-124.
19. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin, 28, 213-218.
20. Marder SR, Meibach RC. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
21. Hedges LV, Olkin I. (1985) Statistical methods for meta-analysis. Academic Press, Orlando.
22. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 295-305.
23. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-40.
24. Min SK, Rhee CS, Kim CE, Kang DY. (1993) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients; a parallel group double-blind comparative trial. Yonsei Medical Journal, 34, 179-190.
25. Peuskens J, The Risperidone Study Group. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel group study versus haloperidol. British Journal of Psychiatry, 166, 712-726.
26. Baldessarini RJ, Cohen BM, Teicher MH. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.
27. De Oliveira IR, Dardennes RM, Amorim ES, Diquet B, de Sena EP, Moreira EC, de Castro-e-Silva EJ, Payan C, Fermanian J, Marcilio C, Samuel-Lajeunesse B. (1995) Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. Fundamental and Clinical Pharmacology, 9, 488-502.
28. De Oliveira IR, de Sena EP, Pereira ELA, et al. (1996) Haloperidol blood levels and clinical outcome: a meta-analyis of studies relevant to testing the therapeutic window hypothesis. Journal of Clinical Pharmacy and Therapeutics, 21, 229-236.
29. Chouinard G, Arnott W. (1993) Clinical review of risperidone. Canadian Journal of Psychiatry, 38 (Suppl. 3), 89-95.
30. Grant S, Fitton A. (1994) Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs, 48, 253-273.
31. Kane JM. (1994) Risperidone: new horizons for the schizophrenic patient. Journal of Clinical Psychiatry, 55 (Suppl.), 3-4.
32. Carman J, Peuskens J, Vangonougden A. (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Clinical Psychopharmacology, 10, 207-213.
33. Borzak S, Ridker PM. (1995) Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Annals of Internal Medicine, 123, 873-877.
34. Screjskij M. (1949) Terapija psichiceskich zobolevanij. Medgiz, Moscow (quoted by 18).
35. Zelen M. (1971) The analysis of several 2 × 2 contingency tables. Biometrika, 58, 129-137.